Chicago Capital LLC Buys 5,097 Shares of Zoetis Inc. (NYSE:ZTS)

Chicago Capital LLC lifted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 1.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 328,331 shares of the company's stock after acquiring an additional 5,097 shares during the quarter. Zoetis makes up approximately 1.5% of Chicago Capital LLC's investment portfolio, making the stock its 29th largest position. Chicago Capital LLC owned approximately 0.07% of Zoetis worth $54,060,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Rakuten Securities Inc. raised its holdings in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the period. Navigoe LLC acquired a new position in Zoetis during the fourth quarter worth approximately $30,000. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis in the fourth quarter valued at approximately $44,000. Sound Income Strategies LLC lifted its position in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in shares of Zoetis during the 4th quarter worth approximately $59,000. Institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president now owns 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.18% of the company's stock.

Zoetis Stock Up 0.0%

NYSE ZTS opened at $164.36 on Tuesday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market cap of $73.18 billion, a price-to-earnings ratio of 30.05, a PEG ratio of 2.78 and a beta of 0.94. The company has a 50 day moving average of $159.07 and a 200-day moving average of $163.75. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.38 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. Zoetis's dividend payout ratio (DPR) is 35.91%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. UBS Group cut their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Stifel Nicolaus cut their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Piper Sandler upped their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. Finally, Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.